Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964506 · ClinicalTrials.gov registry record · Early Phase 1
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
A Early Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Omar Aljitawi.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03964506 is a Early Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Omar Aljitawi. The registered enrollment target is 24 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03964506, a Early Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Omar Aljitawi.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflammation of the mouth or gut) and infection. This study has two cohorts. The first cohort is subjects with acute myeloid leukemia (AML) or Myelodysplastic Syndrome (MDS). The second cohort is subjects with chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), chronic monocytic leukemia, chronic neutrophilic leukemia (CNL), myelofibrosis, and myelodysplastic/myeloproliferative (MDS/MPN) overlap syndrome. The first cohort has completed the recruitment so only the second cohort will be recruited.
Conditions Studied
Interventions
- DRUG Hyperbaric oxygen
Study Locations (1)
New York
- Wilmot Cancer Institute, University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2027-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03964506
The ClinicalTrials.gov registry entry for NCT03964506 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (79% lower). The listed sponsor is Omar Aljitawi, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Hyperbaric oxygen is the first listed.
NCT03964506 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03964506 about?
NCT03964506 is a clinical study titled "Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant". The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflamma...
What is the current status of trial NCT03964506?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2020-07-01. Estimated completion is 2027-03-01.
What conditions does trial NCT03964506 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT03964506?
The interventions under investigation include: Hyperbaric oxygen (DRUG).
Who is sponsoring clinical trial NCT03964506?
This trial is sponsored by Omar Aljitawi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03964506 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
RECRUITING · Early Phase 1
-
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
RECRUITING · Early Phase 1
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
COMPLETED · Early Phase 1
-
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
COMPLETED · Early Phase 1
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.